Therapy News and Research

RSS

'No malignancy risk' with biologic response modifiers

Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.

10 Sep 2012

Adult stem cell technology holds hope for erectile dysfunction treatment

After more than a decade of short-term cures to erectile dysfunction, most aimed at symptoms rather than the underlying issues of nerve damage, a new approach has emerged from adult stem cell technology developed by RNL Bio. Dr. Ji Youl Lee and the RNL Stem Cell Technology Institute (RNL SCTI) team, working at St. Mary's Hospital in Seoul, found in animal studies that adipose (fat) derived adult human stem cells, grown in culture, were very effective in treating cavernous nerve injury.

10 Sep 2012

Islet Sciences licenses noninvasive technology from Winthrop for detecting Beta cell death

Islet Sciences, Inc., a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has exclusively licensed technology from Winthrop University Hospital. This technology is complimentary to the early Beta cell destruction diagnostic that Islet Sciences licensed last month.

10 Sep 2012

New molecular pathway that leads to preeclampsia identified

Preeclampsia is one of the most dangerous conditions for the expectant mother and the unborn child and is characterized by elevated blood pressure and protein in the urine in the last trimester of pregnancy.

10 Sep 2012

Atox Bio AB103 for Necrotizing Soft Tissue Infections granted FDA Fast Track designation

Atox Bio, a clinical stage biotechnology company engaged in the development of novel immunemodulators for severe infections in critically ill patients, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AB103, its lead product, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI).

10 Sep 2012

Data from BioLineRx’s BL-7010 pre-clinical studies on celiac disease

BioLineRx, a biopharmaceutical development company, announced today that BL-7010, an orally available treatment for celiac disease, was found to be safe and well tolerated in pre-clinical studies conducted to date.

10 Sep 2012

Researchers identify many potential therapeutic targets for squamous cell lung cancers

A new paper published online in Nature holds out hope that people with the second most common type of lung cancer may one day benefit from targeted therapies that have transformed treatments for other lung cancer patients.

10 Sep 2012

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury.

10 Sep 2012

Researchers identify genetic variations linked with onset of Barrett's oesophagus

Genetic variations that are linked with the onset of Barrett's oesophagus (BE), a pre-cancerous condition of the lower end of the gullet, have been identified for the first time. The discovery of variations in regions on two chromosomes makes it possible to develop screening tests for people at high risk of developing the disease.

10 Sep 2012

Endocrine Society issues practice guideline for diagnosis and treatment of hypertriglyceridemia

The Endocrine Society today issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of hypertriglyceridemia. Triglycerides are a type of fat found in the blood and are associated with cardiovascular risk. The CPG, entitled "Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline" appears in the September 2012 issue of the Journal of Clinical Endocrinology and Metabolism (JCEM), a publication of The Endocrine Society.

10 Sep 2012

Cedars-Sinai receives CIRM grant to continue study of stem cell therapy for heart disease

A team of Cedars-Sinai Heart Institute stem cell researchers today was awarded a $1.3 million grant from the California Institute of Regenerative Medicine to continue study of an experimental stem cell therapy that treats heart attack patients with heart-derived cells. Earlier this year, data from the first clinical trial of the stem cell treatment showed the therapy helped damaged hearts regrow healthy muscle.

10 Sep 2012

Antibiotic treatment more effective than placebo in patients with mild-to-moderate COPD

Antibiotic treatment with amoxicillin/clavulanate improves moderate exacerbations in patients with mild-to-moderate chronic obstructive pulmonary disease (COPD) and significantly prolongs the time between exacerbations, according to a new study from researchers in Spain.

10 Sep 2012

GSK, University of Cambridge aim to discover and develop new medicines for liver disease

A new collaboration based at the University of Cambridge will aim to discover and develop new medicines to treat liver disease.

10 Sep 2012

UC Irvine receives CIRM grant to advance stem cell-based treatments for AD, retinitis pigmentosa

Efforts to begin human clinical trials using stem cells to treat Alzheimer's disease and retinitis pigmentosa received a $37.3 million boost from the California Institute for Regenerative Medicine during its most recent round of funding on Sept. 5.

10 Sep 2012

Simple assay to improve treatment for idiopathic membranous nephropathy

Simple blood tests could help physicians decide which patients with a particular autoimmune kidney disease can forgo potentially toxic medications and which need to be treated, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

7 Sep 2012

Trevena to present TRV027 Phase 1 clinical data at 16th Annual Heart Failure Society of America Meeting

Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, today announced that it is presenting a poster featuring Phase 1 clinical data on TRV027 at the 16th Annual Heart Failure Society of America Meeting being held in Seattle, WA, September 9th-12th. Trevena is developing TRV027 for the treatment of acute decompensated heart failure.

7 Sep 2012

CIRM awards Cedars-Sinai $1.3M to study stem cell therapy for heart attacks

7 Sep 2012

Children and young patients with chronic HBV infection do have a protective immune response

Scientists from A*STAR's Singapore Institute for Clinical Sciences (SICS), together with clinical collaborators from London , discovered for the first time that children and young patients with chronic Hepatitis B Virus infection (HBV carriers) do have a protective immune response, contrary to current belief, and hence can be more suitable treatment candidates than previously considered.

7 Sep 2012

Mammalian target of rapamycin inhibitors can prevent radiation-induced tissue damage

Radiation therapy is one of the most widely used cancer treatments, but it often damages normal tissue and can lead to debilitating conditions. A class of drugs known as mammalian target of rapamycin (mTOR) inhibitors can prevent radiation-induced tissue damage in mice by protecting normal stem cells that are crucial for tissue repair, according to a preclinical study published by Cell Press in the September issue of the journal Cell Stem Cell.

7 Sep 2012

Married patients with locally advanced lung cancer likely to survive longer after treatment

Married patients with locally advanced lung cancer are likely to survive longer after treatment than patients who are single, according to a study by researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore.

7 Sep 2012

Therapy News and Research

'No malignancy risk' with biologic response modifiers

Adult stem cell technology holds hope for erectile dysfunction treatment

Islet Sciences licenses noninvasive technology from Winthrop for detecting Beta cell death

New molecular pathway that leads to preeclampsia identified

Atox Bio AB103 for Necrotizing Soft Tissue Infections granted FDA Fast Track designation

Data from BioLineRx’s BL-7010 pre-clinical studies on celiac disease

Researchers identify many potential therapeutic targets for squamous cell lung cancers

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Researchers identify genetic variations linked with onset of Barrett's oesophagus

Endocrine Society issues practice guideline for diagnosis and treatment of hypertriglyceridemia

Cedars-Sinai receives CIRM grant to continue study of stem cell therapy for heart disease

Antibiotic treatment more effective than placebo in patients with mild-to-moderate COPD

GSK, University of Cambridge aim to discover and develop new medicines for liver disease

UC Irvine receives CIRM grant to advance stem cell-based treatments for AD, retinitis pigmentosa

Simple assay to improve treatment for idiopathic membranous nephropathy

Trevena to present TRV027 Phase 1 clinical data at 16th Annual Heart Failure Society of America Meeting

CIRM awards Cedars-Sinai $1.3M to study stem cell therapy for heart attacks

Children and young patients with chronic HBV infection do have a protective immune response

Mammalian target of rapamycin inhibitors can prevent radiation-induced tissue damage

Married patients with locally advanced lung cancer likely to survive longer after treatment

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News